How will the HHS proposed rule changes to Medicare Part D and Medicaid drug rebate safe harbors impact pharmaceutical product net costs for PBMs?

Higher net costs after the implementation of the proposed rule 50%

Lower net costs after the implementation of the proposed rule 13%

No impact, net costs will be at the same levels as today 38%

Give others the chance to vote.